Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%. Meanwhile ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in a research report issued on Tuesday,Benzinga reports. The firm presently ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...

Financial disclosures released ahead of confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the health ...

Robert F. Kennedy Jr. will be pulling his investments from two biotechs if he is confirmed to lead the U.S. Department of ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP. Type ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $41.92, moving -1.2% from the previous trading session.